Results 81 to 90 of about 13,963,189 (308)

The microbiome in human skin aging

FEBS Letters, EarlyView.
Age‐related skin changes encompass the well‐known visible phenotypic alterations, together with microbiome dysbiosis and a series of molecular aging hallmarks. These hallmarks characterize not only a fully stablished aged phenotype but also the skin aging process itself.
Manuel Huerta Arana, Cornelia Wiegand, Omid Omrani, Mario Fabri   +3 more
wiley   +1 more source

Ligand‐dependent transcriptional heterogeneity in cell cycle gene expression delays G1/S entry

FEBS Letters, EarlyView.
EGF and HRG induce distinct G1/S progression programs in ErbB2‐amplified BT474 breast cancer cells. Despite activating the potent ErbB2–ErbB3 heterodimer, HRG does not accelerate cell‐cycle entry. Instead, EGF promotes earlier restriction‐point passage via ERK–FOS signaling, whereas HRG activates the AKT–MYC axis, driving transcriptional heterogeneity ...
Ririn Rahmala Febri, Ayaka Nagasato‐Ichikawa, Keita Iida, Shuhei Kimura, Akira Imamoto, Mariko Okada   +5 more
wiley   +1 more source

The heterodimeric amino acid transporters (HAT) of the SLC7/SLC3 family: A structure−function relationships and relevance to human pathology

FEBS Letters, EarlyView.
Heterodimeric amino acid transporters consist of SLC7 and SLC3 family proteins arranged in a conserved structural organization. They regulate nutrient transport across cell membranes, supporting essential cellular functions. These transporters also contribute to xenobiotic/drug uptake and distribution.
Mariafrancesca Scalise, Tiziano Mazza, Raffaella Scanga, Lara Console, Michele Galluccio, Cesare Indiveri   +5 more
wiley   +1 more source

Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation

, 2017
Nishant Patel,1 Pingping Wu,2 Haijun Zhang1 1Department of Oncology, Zhongda Hospital, Medical School, Southeast University, 2Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, People’s Republic of China Objectives: Gefitinib, a ...
Patel N, Wu P, Zhang H
core  

Cost Effectiveness Analysis of Clinically Driven versus Routine Laboratory Monitoring of Antiretroviral Therapy in Uganda and Zimbabwe [PDF]

, 2012
BACKGROUND: Despite funding constraints for treatment programmes in Africa, the costs and economic consequences of routine laboratory monitoring for efficacy and toxicity of antiretroviral therapy (ART) have rarely been evaluated.
Amurwon, Jovita, Abdel G. Babiker (158530), Darbyshire Janet, Antonieta Medina Lara (168787), Antonieta Medina Lara, Charles F. Gilks (164480), Munderi Paula, Wakaholi, Barbara Nyanzi, Walker, A Sarah, Babiker, AG, Elly Katabira, Paula Munderi, Reid Andrew, Kasirye, Ronnie, James Hakim, Andrew Reid, Gibb, Diana M., Janet Darbyshire (59117), Jesse Kigozi (168794), Katabira Elly, Gilks, CF, Gilks, Charles F, Kityo Cissy, Darbyshire, J, Jovita Amurwon, Cissy Kityo, Walker A. Sarah, Kigozi, Jesse, Mugyenyi Peter, Barbara Nyanzi Wakaholi, Gibb, DM, Mugyenyi, Peter, Lara, AM, Walker, AS, Muchabaiwa Lazarus, Reid, Andrew, Peter Mugyenyi (168847), Darbyshire, Janet, Diana M. Gibb (164420), Medina Lara Antonieta, Ssali Francis, Kityo, Cissy, Grosskurth Heiner, Grosskurth, Heiner, Abdel G Babiker, Ruben E. Mujica Mota (168817), Kasirye Ronnie, Jesse Kigozi, Wakaholi, BN, Ssali, Francis, Ssali, F, Lazarus Muchabaiwa, Medina Lara, Antonieta, Hakim James, Walker, A. Sarah, Peter Mugyenyi, Janet Darbyshire, Gilks, Charles F., Team, DARTT, DART Trial Team, Diana M Gibb, Muchabaiwa, L, Elly Katabira (10701), A Sarah Walker, Kasirye, R, Ronnie Kasirye (168825), Paula Munderi (164469), Katabira, Elly, Muchabaiwa, Lazarus, Munderi, P, Hakim, J, Gibb, Diana M, Barbara Nyanzi Wakaholi (168811), Mota, Ruben E. Mujica, Gilks Charles F., Amurwon Jovita, Jovita Amurwon (168800), James Hakim (164478), Babiker, Abdel G, Amurwon, J, Charles F Gilks, Kityo, C, Nyanzi Wakaholi, Barbara, Babiker, Abdel G., Gibb Diana M., Mota, REM, Cissy Kityo (168842), Mujica Mota, Ruben E, Heiner Grosskurth (37057), Ruben E Mujica Mota, Reid, A, Kigozi Jesse, Francis Ssali, Mujica Mota Ruben E., Andrew Reid (168831), A. Sarah Walker (145609), Heiner Grosskurth, Lara, Antonieta Medina, Katabira, E, Ronnie Kasirye, Munderi, Paula, Grosskurth, H, Hakim, James, Francis Ssali (158549), Lazarus Muchabaiwa (168805), Kigozi, J, Mugyenyi, P, Nyanzi Wakaholi Barbara, Babiker Abdel G.   +108 more
core   +1 more source

A context‐dependent modulatory role for eIF6 in acquired resistance to vemurafenib in melanoma

FEBS Letters, EarlyView.
Acquired resistance to vemurafenib upregulates the translation factor eIF6 in melanoma cells. Silencing eIF6 in resistant cells reduces proliferation and partially restores drug sensitivity, whereas its overexpression increases sensitivity across melanoma lines regardless of BRAF status, via modulation of mTOR, S6K, and MAPK signaling.
George Kyriakopoulos, Antonia Petropoulou, Alexandra Anastogianni, Angelina Bania, Vassilis Stamatakis, Argyris Alexiou, Chi‐Ping Day, Glenn Merlino, Katerina Grafanaki, Constantinos Stathopoulos   +9 more
wiley   +1 more source

Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review

Therapeutic Advances in Medical Oncology, 2017
We reviewed randomized phase II/III trials comparing first- or second-line endocrine therapy as monotherapy or in combination with targeted therapies for treatment of postmenopausal patients with hormone receptor-positive advanced breast cancer.
Tomás Reinert, Carlos H. Barrios
doaj   +1 more source

Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab

ESMO Open, 2019
Background The role of continuing anti-HER2 therapy beyond progression on front-line therapy in patients with metastatic HER2 positive gastro-oesophageal cancer (GEC) is unclear.
Christopher Nevala-Plagemann, Justin Moser, Glynn Weldon Gilcrease, Ignacio Garrido-Laguna   +3 more
doaj   +1 more source

Second-line antiretroviral therapy in resource-limited settings: The experience of Médecins Sans Frontières

, 2008
Second-line antiretroviral therapy in resource-limited settings: The experience of Médecins Sans ...
D OBrien (13402917), P Humblet (13402710), M Pujades-Rodríguez (13402914), A Calmy (13198557)   +3 more
core  

Metastatic niche shaped by host factors influences disseminated cancer cell fate

FEBS Letters, EarlyView.
Metastasis is shaped not only by cancer cells but also by the environments they encounter. This review explores how factors such as aging, diet, the microbiome, lifestyle, and environmental exposures remodel organ‐specific niches in the lung, liver, bone, and brain, influencing where metastatic cells survive, remain dormant, or grow, and ultimately ...
Gwennan Delyth Ward, Álvaro Ruiz‐Tabas, Patricia Altea‐Manzano   +2 more
wiley   +1 more source